The FDA on March 15, 2017 granted accelerated approval to KEYTRUDA® injection for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy. KEYTRUDA® is a product of Merck Sharp & Dohme Corp.
Bottom Ad
Advertisement
Subscribe
